These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23151203)

  • 1. Interferon stimulated genes and hepatitis C virus infection.
    Asselah T
    J Interferon Cytokine Res; 2012 Dec; 32(12):557-62. PubMed ID: 23151203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal treatment with telaprevir for chronic HCV infection.
    Jesudian AB; Jacobson IM
    Liver Int; 2013 Feb; 33 Suppl 1():3-13. PubMed ID: 23286840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin.
    Kwo PY
    Liver Int; 2012 Feb; 32 Suppl 1():39-43. PubMed ID: 22212570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
    Ramachandran P; Fraser A; Agarwal K; Austin A; Brown A; Foster GR; Fox R; Hayes PC; Leen C; Mills PR; Mutimer DJ; Ryder SD; Dillon JF
    Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
    Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
    PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
    Forestier N; Zeuzem S
    Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.
    Sultanik P; Mallet V; Lagaye S; Casrouge A; Dorival C; Barthe Y; Fontaine H; Hézode C; Mottez E; Bronowicki JP; Carrat F; Theodorou I; Abel L; Gayat E; Fontanet A; Pol S; Albert ML;
    Liver Int; 2015 Jul; 35(7):1833-44. PubMed ID: 25556540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon free therapy with direct acting antivirals for HCV.
    Asselah T; Marcellin P
    Liver Int; 2013 Feb; 33 Suppl 1():93-104. PubMed ID: 23286852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
    Asselah T; Marcellin P
    Liver Int; 2012 Feb; 32 Suppl 1():88-102. PubMed ID: 22212578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
    Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What's new in HCV genotype 2 treatment.
    Mangia A; Mottola L
    Liver Int; 2012 Feb; 32 Suppl 1():135-40. PubMed ID: 22212584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir for chronic hepatitis C virus infection.
    Jesudian AB; Jacobson IM
    Clin Liver Dis; 2013 Feb; 17(1):47-62. PubMed ID: 23177282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of chronic hepatitis viral C: new associations].
    Ouzan D
    Presse Med; 2013 Jun; 42(6 Pt 1):977-82. PubMed ID: 23021659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Boceprevir for chronic HCV genotype 1 infection.
    Limaye AR; Draganov PV; Cabrera R
    N Engl J Med; 2011 Jul; 365(2):176; author reply 177-8. PubMed ID: 21751914
    [No Abstract]   [Full Text] [Related]  

  • 16. The future for the treatment of genotype 4 chronic hepatitis C.
    Esmat G; El Raziky M; El Kassas M; Hassany M; Gamil ME
    Liver Int; 2012 Feb; 32 Suppl 1():146-50. PubMed ID: 22212586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral strategies in hepatitis C virus infection.
    Sarrazin C; Hézode C; Zeuzem S; Pawlotsky JM
    J Hepatol; 2012; 56 Suppl 1():S88-100. PubMed ID: 22300469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal treatment with boceprevir for chronic HCV infection.
    Maasoumy B; Manns MP
    Liver Int; 2013 Feb; 33 Suppl 1():14-22. PubMed ID: 23286841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telaprevir for the treatment of chronic hepatitis C infection.
    Muir AJ
    Expert Rev Anti Infect Ther; 2011 Dec; 9(12):1105-14. PubMed ID: 22114960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.